MOBX · Mobix Labs, Inc.

Mobix Labs operates at the intersection of wireless connectivity and high-reliability filtering, targeting mission-critical applications in defense, aerospace, and medical sectors where failure costs are prohibitive. Post-SPAC merger in December 2023, the company has pursued inorganic growth via acquisitions—EMI Solutions ($10.9M, Dec 2023) for EMI filters and RaGE Systems ($9.5M, May 2024) for mmWave/5G expertise—driving FY2025 revenue to $9.9M (54% YoY growth, products $6.0M, services $3.9M). However, scale remains nascent with 46 employees, heavy customer reliance (Leidos 50% revenue), and persistent losses ($37.7M operating loss, $160.7M accumulated deficit) signaling high burn amid R&D and integration costs. Cash of $3.3M at FYE 2025 underscores liquidity strain, prompting repeated financings including this $3M 10% convertible note (conversion ≤$3.34 or 85% 8-day VWAP, anti-dilution protection) whose resale shares (2.5M, ~24% of 10.4M outstanding Class A) could pressure the $2.92 share price. No proceeds flow to Mobix from resale, but note funds target working capital amid Nasdaq battles (resolved via April 2026 1:10 reverse split after $1 bid/MVLS issues). Dual-class structure entrenches management control (Class B 10x voting), while material control weaknesses and going concern doubt amplify execution risks. Competitive moat rests on U.S.-based HiRel manufacturing, IP portfolio, and acquisition synergies, but faces giants like Qualcomm/NXP in mmWave and Amphenol in EMI. Strategy hinges on scaling acquired revenue streams while commercializing mmWave ICs, but dilution from 2.6M warrants, earnouts, and convertibles (~25% overhang) plus debt servicing could constrain near-term stability. Investors should weigh defense tailwinds against cash burn and concentration vulnerabilities.